Document 1221
 DOCN  M9591221
 TI    The prognostic value of plasma viremia in HIV-infected patients under
       AZT treatment: a two-year follow-up study.
 DT    9509
 AU    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C;
       Colimon R; Cartier F; Laboratoire de Virologie, Hopital Pontchaillou,
       Rennes, France.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jul 1;9(3):243-8.
       Unique Identifier : AIDSLINE MED/95308199
 AB    To determine the prognostic value of plasma viremia in long-term
       zidovudine (AZT)-treated HIV-infected patients, HIV-1 plasma viremia
       (PV) was quantified in 28 HIV-infected patients before and during AZT
       long-term treatment; the follow-up also included p24 antigenemia and CD4
       cell counts. The variations of these markers during the follow-up
       period, the correlation with the clinical outcome (progressors versus
       nonprogressors), and the discrepancies between PV and surrogate markers
       were then analyzed. A significant and stable decrease in PV titer was
       observed in only nonprogressors (Friedman test, p < 0.005). At the end
       of follow-up, 11 (73%) of the 15 non-progressors were PV responders
       (patients who remained or became PV- long-term), whereas all the 13
       progressors were PV nonresponders (patients who remained or became PV+).
       These results indicated a strong correlation between PV and clinical
       outcome (Fischer's exact test, p < 0.0001). The persistence, increase,
       or reappearance of viral replication appeared to be an important
       predictor of poor clinical outcome in HIV-infected patients under AZT
       treatment. This finding could provide a rational basis to help the
       clinician's decision in the clinical treatment of HIV-infected patients.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/PHYSIOPATHOLOGY/
       VIROLOGY  CD4 Lymphocyte Count  Female  Follow-Up Studies  Human  HIV
       Core Protein p24/BLOOD  HIV Infections/*DRUG
       THERAPY/PHYSIOPATHOLOGY/VIROLOGY  HIV-1/*DRUG EFFECTS/PHYSIOLOGY  Male
       Prognosis  Prospective Studies  Viremia/*DRUG
       THERAPY/PHYSIOPATHOLOGY/VIROLOGY  Virus Replication
       Zidovudine/PHARMACOLOGY/*THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).